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Moderators and predictors of response to cognitive behaviour therapy for 
pediatric obsessive-compulsive disorder: A systematic review.
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Abstract 
We report a systematic review of moderators of CBT efficacy for pediatric OCD relative to 
other treatments. CENTRAL, MEDLINE, EMBASE, CINAHL, and PsycINFO were 
searched for RCTs reporting on effect moderation for CBT outcomes. Five studies (N = 365) 
examined 17 variables with three significant moderators identified. Compared to pill-placebo, 
CBT monotherapy was not effective for children with a family history of OCD but was for 
those without a family history.  For children with a family history, CBT plus sertraline 
efficacy was attenuated but remained significant. For children with tics, CBT but not 
sertraline remained superior to pill-placebo. For non-responders to initial treatment with 
CBT, continuing CBT was inferior to commencing sertraline for those with tics but was not 
different for those without tics. A supplementary review identified older age, symptom and 
impairment severity, co-morbidity and family accommodation as consistent predictors of a 
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poorer outcome to CBT. Current evidence for moderation effects is post-hoc, from single 
RCTs, has small Ns and requires replication. The review identifies family history of OCD 
and the presence of tics as factors requiring further examination in properly conducted trials 
and about which clinicians need to show care in their treatment recommendations.  
 
Keywords: pediatric OCD; CBT; effect moderators; predictors.  
 
 
1. Introduction 
Obsessive-Compulsive Disorder (OCD) in children and youth is a serious mental 
disorder associated with significant distress and marked interpersonal, academic and 
occupational impairments (Piacentini et al., 2003), which over time can have major 
detrimental impacts on children’s psychosocial development and on their families’ ongoing 
well-being (Stewart et al., 2004). While SSRI medication and cognitive behavioural therapy 
with exposure and response prevention (CBT), either combined or alone, have been identified 
as efficacious initial treatments (Ivarsson et al., 2015; March et al., 2004; O’Kearney et al., 
2010), CBT is usually considered the treatment of choice when available because of its lower 
risk-to-benefit ratio compared to medication and higher acceptability by patients and their 
families.   
There is significant variability in how well children and adolescents with OCD 
respond to CBT with a notable proportion showing limited clinically significant benefits. 
Less than half (39%) of those treated with CBT show adequate remission of their symptoms 
(De Haan, 2006; March et al., 2004).
  
This compares to about 22% remission rates following 
monotherapy with an SSRI, and 54% when CBT is combined with an SSRI (March et al., 
Moderators of CBT for pediatric OCD 3 
 
2004). These rates of treatment response highlight the importance of improving the capability 
of clinicians to provide recommendations which optimise the initial treatment for a particular 
patient. Currently, practice guidelines recommend that CBT be offered as the first line 
treatment for patients with mild to moderate symptom severities and that combined CBT and 
SSRI be used as the initial treatment in more severe cases (American Academy of Child and 
Adolescent Psychiatry, AACAP, 2010), or that an SSRI be added when the patient has not 
shown an adequate response to CBT alone (National Institute for Health and Clinical 
Excellence [NICE], 2005). While the severity of the OCD symptoms may be one factor 
guiding treatment recommendation, the decision should be based primarily on evidence about 
which pre-treatment characteristics of the patient or his/her context moderate the chances of 
the patient responding better to one treatment compared to another in randomised controlled 
trials.  
There are increasing calls for this question to become a central one in the design and 
analysis of controlled trials of treatments for mental disorders including those in children and 
adolescents (Bloch, 2014; Kraemer et al., 2006).  Not only can evidence about factors which 
differentiate subgroups of children with OCD who respond better to one treatment compared 
to another optimise treatment outcomes, it can also prevent delivery of less or unhelpful, or 
even harmful treatments to individual patients. Despite these calls, empirical work in regard 
to outcomes for CBT for pediatric OCD has overwhelming focused on factors which are 
associated with the strength of the CBT treatment effect, i.e. predictors, with several reviews 
integrating the evidence about predictors of treatment outcome (Ginsburg et al., 2008; Torp et 
al., 2015).  Only one study (McGuire et al., 2015) has previously attempted to bring together 
some of the evidence about moderators in a review and analyses of factors which predict the 
relative treatment efficacy of CBT compared to some comparators. This study used between 
study variability in the average value of possible moderators to estimate, using meta-
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regression, the strength of the association between these factors and study effect size. It found 
a positive association between the percentage of children and adolescents in the study with 
co-occurring anxiety disorders and the effect of CBT relative to a waitlist control. The study 
also found a positive association between the percentage of children and adolescents in the 
study with co-morbid Tourette’s or Tic disorder and the benefits of CBT relative to treatment 
with relaxation training. While informative, these results are limited because studies 
examining factors which may moderate the comparative efficacy of CBT compared to other 
treatments with demonstrated efficacy, particularly medication or combined CBT plus 
medication, were not included in the analysis. Choice of comparator is crucial for clinicians 
in weighing up the evidence about the initial treatment of a child with OCD. In addition, 
while McGuire et al., (2015) included some clinically useful potential moderators such as 
initial OCD severity and co-morbidity, it also considered factors such as study quality and 
number of sessions which are not outcome moderators and cannot contribute to clinical 
decisions about which children may respond better to CBT and which may not (Kraemer et 
al., 2006).   
The approach we take here is to use systematic review methodology to identify all 
RCT trials of CBT compared to any comparator which reported on a pre-treatment 
characteristic of the participants, their illness, or the context, and tested this characteristic as a 
moderator of CBT efficacy relative to the comparator. We document these findings and pool 
them when appropriate. This method has advantages for clinical decision making over the use 
of meta-regression particularly when there may be only a small number of studies with 
relevant data as in the McGuire et al. (2015) review.  First, it preserves the temporal 
connection of the moderators to the treatments and their outcomes and the control for 
individual-level confounds of comparative treatment effects provided by randomisation in the 
initial study design. Second, each study analysis provides an independent estimate of the 
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strength of the moderator effect as well as, for significant estimates, the strength of the 
association between the moderator and outcome for the CBT and comparator groups. This 
allows consideration of the consistency of any finding across studies as well as predictions 
about the size of the relative response to CBT for individual patients with the moderator 
characteristic. Our approach also avoids meta-regression’s inherent limitations for drawing 
inferences about how individual children might response to CBT (Thompson & Higgins, 
2002). These problems include little between-study variability in the moderator tested, over 
interpretation of very small sets of studies and invalid conclusions because the relationship 
between treatment response and the average level of a moderator across trials may not be the 
same as its relationship with between-individual variability in the moderator s within an RCT 
(‘aggregation bias’; Aquinis et al., 2005; Higgins, 2001; Thompson & Higgins, 2002).   
In addition to its value in treatment planning, evidence about moderators of treatment 
response can assist researchers in gaining further understanding of possible causal models of 
the different mechanisms of action of treatments for pediatric OCD. Contemporary models of 
the mechanism by which the key component of CBT (exposure with response prevention) has 
its effect propose that inhibitory learning processes are critical in the development of non-
threat associations during exposure (Craske et al., 2014). Identifying factors which moderate 
these processes relative to medication or combined CBT plus medication could provide 
important clues regarding how certain child characteristics relate to fear acquisition and new 
non-threat learning, and how to adapt and integrate psychological and pharmacological 
treatments for OCD to produce lasting benefits. It also allows hypotheses about mechanisms 
to be tested in RCTs with children and adolescents selected for the potential moderators. 
Another source of information about possible moderators is the evidence about pre-
treatment factors which are consistently associated with treatment outcome (i.e. predictors).  
While evidence about non-specific predictors has less relevance to evidence-based clinical 
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decision-making  about the choice of initial treatment, identifying predictors of treatment 
response can provide a focus for subsequent research on possible moderators, and on 
components of CBT which require further development or adaption for specific groups of 
patients in order to optimise outcomes (Kraemer, et al., 2006).  We therefore include a 
supplementary review of the evidence of pre-treatment factors which predict CBT outcome to 
ensure that recommendations for future work on moderators of CBT outcome include all 
potential factors, and not only those which have been investigated in moderator studies.   
 
1.1 Aims 
The current study provides the first synthesis of evidence in a systemic review addressing the 
question: For children and youth under 18 years of age with OCD, which factors moderate 
treatment outcome for CBT relative to a comparator in RCTs? The review was supplemented 
by a systematic review of the evidence about pre-treatment factors which are associated with 
response to CBT. , 2 Method 
2.1 Study design and protocol 
The review was undertaken using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines (PRISMA; Moher et al., 2009). A review protocol 
was registered with the Prospero International prospective register of systematic reviews 
(O’Gorman et al., 2014; Prospero 2014:CRD42014009386).   
2.2 Eligibility criteria 
Type of studies.  
Two types of studies were included. 1) To address questions related to the moderation 
of CBT efficacy, eligible studies had to be RCTs or controlled trials of CBT with quasi-
randomised allocation of participants which included an individual CBT arm.  Eligible 
studies had to report on measures of moderators at baseline (prior to randomisation) and 
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examine these statistically as moderators of the effect of CBT relative to a comparator. 2) To 
address questions related to factors which predict CBT treatment effects, non-controlled trials 
of CBT were also included. Eligible studies had to measure the predictor at baseline (prior to 
randomisation) and report the association of these measures with the size of CBT effect post-
treatment, at follow-up or across time.  
Types of participants.  
Participants in eligible studies for both moderator and predictor analyses had to be 
children or youth aged 18 years of age or less at time of study entry, who were diagnosed 
with OCD using explicit criteria described in the study. Studies had to include an intervention 
nominated as CBT monotherapy which included ERP as a component. RCTs were included 
regardless of type of comparator (active medication, combined CBT plus medication, pill 
placebo, other psychotherapy, wait list or treatment-as-usual). Studies of efficacy of 
medication were included, as well as studies which combined CBT and medications, as long 
as there was a CBT monotherapy arm.  
2.3 Measures  
Moderator or predictor variables were any study-defined characteristics of patients, 
their disorder or their environment (family or community) measured at base-line that was 
examined statistically in regard to the following.  For moderators, how they interacted with 
the between group intervention effect on a primary OCD outcome, or how they influenced 
the effect size between CBT and a comparator (standardised mean difference or relative risk 
for the primary outcome). For predictors, how strongly they were associated with the primary 
outcome for the CBT group.   
Primary outcome measures included: a) post and follow-up total OCD severity 
measured by the gold standard CY-BOCS; and b) percentage reductions on total CY-BOCS 
severity prior to post-treatment or prior to follow-up. 
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2.4 Search Methods for identification of studies 
Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, 
CINAHL, and PsycINFO were searched until June 2017 using search terms:  
“Obsessive compulsive disorder”; “child” (including the terms “adolescent”, “pediatric”, and 
variants thereof); and “cognitive behaviour therapy” (including psychotherapy, behaviour 
therapy, exposure therapy, and cognitive therapy). Hand-searching identified theses, 
registered trials and conference proceedings which were accessed by contacting the study 
author or the clinical trial databases.  
The search results were merged using reference management software and duplicate 
records of the same report were removed.  Two reviewers examined titles and abstracts to 
remove obviously irrelevant reports. The full text of the potentially relevant reports were 
retrieved and multiple reports of the same study linked. Two reviewers separately examined 
the full-text reports for eligibility and conferred to make a final decision on study inclusion. 
2.5 Assessment of risk of bias  
Moderator studies.  
The check-list of methodological criteria proposed by Pincus (Pincus, Miles, Froud, 
Underwood, Carnes & Taylor, 2011) for assessment of studies of moderators of treatment 
effects was used to assess risk of bias in moderator studies.  Two reviewers examined the 
included studies for these criteria: were the moderator analyses planned; was the potential 
factor measured prior to randomisation; was a valid measure of the factor used; was there a 
test of the interaction; were subgroup outcomes reported; and, was the sample size adequate.   
Predictor studies. 
 While there is no consensus criteria for assessing risk of bias in predictor studies, 
some similar criteria to the moderator studies can be applied.  We report on the type of study 
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(control; open); type of participant (recruited; referred for treatment); numbers of predictors 
in each study; the sample size, and the pre- to post duration.  
2.6 Data extraction and management 
Data extraction was completed by two reviewers independently. Data were extracted 
for the following variables: study sample size, age details of participants, proportion of 
females, diagnostic criteria used, type of comparator, primary OCD outcome (CY-BOCS 
total), reported statistics, length of follow-up, number of participants in the analysis and 
numbers in each subgroup for significant interaction (moderation) effects, effect sizes, p 
values and confidence intervals.   
2.7 Data analysis  
 For moderators, we report the value of the test of the interaction, its significance and 
for any significant interactions, the effect size for the subgroup comparisons (Cohen’s d; 95% 
CIs; p value). For predictors, we report first order correlation coefficients (r) between the pre-
treatment factor and OCD outcome. When a study reported another estimate of association 
(χ2, B) or a test of difference for participants categorised by level of predictor (t, F), we used 
standard methods (Lipsey & Wilson, 2001; Rosenthal, 1994) to convert the effect size to a 
correlation coefficient (r). Meta-analysis was conducted using MedCalc for windows 
(MedCalc, 2017) with random effects models.  Pooled effect sizes were estimated using the 
Hedges-Olkin method (Hedges & Olkin, 1985) when three or more independent effect sizes for 
the same factor were extracted and statistical heterogeneity between the effect sizes was no 
more than moderate (I
2 <
=60%).    
2. Results 
3.1 Search Results  
Figure 1 outlines the flow of studies through the study’s inclusion and exclusion 
processes.  Full texts of 69 articles were reviewed with 34 rejected at this point.  Most of the 
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rejected studies (n=26) did not present statistical analyses of moderation or tests of 
association for predictors. Other reasons for exclusion were that studies did not measure 
putative moderators at baseline, presented associations with a non-OCD outcome or only 
with an OCD subcomponent, did not include a CBT monotherapy arm or did not disaggregate 
results for the CBT monotherapy arm. The 35 included studies consisted of 4 which 
presented results for a moderator interaction, 30 which reported on predictor associations, and 
one which reported on both moderator and predictor effects.   
3.2 Study characteristics 
Moderator studies.  
Table 1 provides the characteristics of the studies for the moderator analyses (Barrett 
et al., 2004; Bolton et al., 2011; Garcia et al., 2010; March, et al., 2007; Skarphedinsson et 
al., 2015). The studies report results from 4 RCTs with a total of 365 participants conducted 
in Australia, Norway, UK and USA. Two (Barrett et al., 2004; Bolton et al., 2011) report 
moderator effects as part of the RCT outcome report, while two (March et al., 2007; Garcia et 
al., 2010) provide reports of subsequent analyses of data from a single RCT (POTS, March et 
al., 2004).  One study (Skarphedinsson, et al., 2015) reports moderation outcomes for 
continuing CBT compared to switching to sertraline for children who failed to respond to an 
initial course of CBT.  Details of the risk of bias assessment of the studies are presented in 
Table 2. The main risks are the lack of power analysis; very small numbers in the sub-groups; 
lack of a-priori predictions, and inadequate reporting of the statistics for non-significant 
interactions and sub-group effects.  
Predictor studies. 
 The characteristics of the 31 studies identified as reporting predictors of outcome of 
CBT are presented in Appendix A of the supplementary material. Thirty-three different 
predictors across 7 domains (demographic; OCD related; concurrent treatment; co-morbidity; 
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family functioning; neuropsychological performance; pathophysiology) were identified.  
Most studies were of children referred for treatment rather than selected children who met 
specified inclusion criteria, and most were un-controlled studies. Several reports contained 
evidence on different predictors from single RCTs.  Duration of study through to post 
treatment ranged from 4 weeks to 18 weeks. The total number of participants for the predictor 
analyses could not be calculated because many of the studies report on different predictors 
from the same sample of participants or from open trials with accumulating numbers 
presented in different reports. Study sample size for estimating individual effects ranged from 
12 to 269.   
3.3. Moderator outcomes  
Table 3 summaries the results of the studies for the moderator analyses. No pooling 
was possible because of the small number of studies for each moderator. Three significant 
moderator by treatment interactions were identified. Using data from the POTS trial, March 
et al. (2007) reported that the presence of tics was an effect moderator for treatment 
outcomes.  The analyses of subgroups indicated that the presence of tics most strongly 
impacted on the efficacy of sertraline compared to pill placebo, but not on the efficacy of 
CBT monotherapy or of CBT combined with sertraline relative to a pill placebo control. 
Numbers in the sub-groups are very small, but only the sertraline versus placebo comparison 
for children with tics showed no treatment effect.  Skarphedinsson et al. (2015) also reported 
a significant moderation effect for the presence of tics.  In this study of children who did not 
respond to an adequate initial trial of CBT, continuing CBT monotherapy was inferior to 
sertraline monotherapy for those with tics, but was not different from sertraline in those 
without tics.  
Using data from the POTS study, Garcia et al., (2010) reported that a history of OCD 
in first degree relatives moderated the efficacy of CBT. Compared to a pill placebo, CBT 
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monotherapy had a non-significant effect in children with a family history but was effective 
in children without a family history.  Family history had no impact on the efficacy of 
sertraline monotherapy compared to the placebo. While the combined treatment was effective 
in both groups of children relative to the placebo, the size of its effect for children with a 
family history was attenuated relative to the effect size for children without a family history.  
Age by treatment effects were not significant (Barrett et al., 2004; Bolton et al., 2011; Garcia 
et al., 2010).  All other factors investigated were not significant as interactions with treatment 
group (Garcia et al., 2010).  
3.4. Predictor outcomes 
Table 4 presents the results for the predictors, organised into predictor type and 
specific predictors.  There were significant pooled effects showing poorer responsiveness to 
CBT was predicted by older age, higher OCD symptom severity, higher level of OCD-related 
impairment, higher level of depressive symptoms, the presence of any co-morbid mental 
disorder, and higher family accommodation of the child’s symptoms. The pooled effect for 
the presence of medication at pre-treatment was not significant.  
3. Discussion 
4.1. Main findings 
The available best evidence about factors which may influence the relative efficacy of 
CBT for pediatric OCD compared to other efficacious treatments is still preliminary and 
requires replication. This systematic review, however, allows several tentative conclusions 
and suggestions for further exploration. First, children with a family history of OCD may not 
benefit from CBT alone relative to a pill placebo.  Second, children with tics may do better 
with CBT than with medication alone. Third, the co-occurrence of a Tic disorder in children 
and adolescents who fail to respond to an initial course of CBT may be associated with an 
inferior response to continued CBT as compared to switching to sertraline. Fourth, there is no 
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evidence from RCTs to conclude that higher initial severity of OCD symptoms moderates the 
response that a patient will have to CBT monotherapy compared to response to medication.  
Fifth, severity of OCD symptoms, along with higher initial levels of impairment, depressive 
symptoms, presence of co-morbidity with another mental disorder, and how the child’s OCD 
is responded to within the family, all predict a higher level of OCD symptoms after CBT.  
Leckman et al. (2009) have suggested a negative influence of family history of OCD 
on CBT efficacy and our systematic review of the literature identified one study (Garcia et 
al., 2010) which reported evidence that confirmed a robust moderation effect of family 
history. This evidence indicated that despite CBT being effective for children and adolescents 
without a first degree relative with OCD, for those with a family history, CBT did not show 
benefits over a pill placebo. The efficacy of CBT when combined with an SSRI was 
attenuated for children and youth with a family history of OCD, compared to its efficacy for 
those without a family history. Nevertheless, combined treatment remained efficacious for 
patients with a family history and not less so than SSRI monotherapy.  The findings suggest 
that while CBT alone may not be the appropriate initial treatment for children with a family 
history of OCD, even for these children, CBT may provide benefits when combined with an 
SSRI compared to using an SSRI by itself.  
There is no evidence that the presence of a co-morbid Tic disorder in pediatric OCD 
is associated with reduced benefits for CBT alone or for combined treatment. Evidence from 
one RCT (March et al., 2007) showed that using SSRI monotherapy as an initial treatment for 
children with co-morbid Tic Disorder has no benefit. There was some evidence, nevertheless, 
that the presence of tics may differentiate a group of non-responders to an initial course of 
CBT monotherapy who benefit from switching to an SSRI more than they benefit from 
continued CBT (Sharphedinsson et al., 2015).  The explanation for this latter finding is 
unclear.  It may reflect the impact on the initial response to CBT of other co-morbidities 
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which are associated with Tic disorders, such as ADHD or disruptive behavior disorders. 
Alternatively, it might indicate that there is a subgroup of CBT non-responders who have a 
specific pattern or blend of OCD and tic symptoms that requires a wider array of treatment 
approaches than CBT.  Unfortunately, there is very little evidence about the factors which 
predict outcomes for either continuing CBT or adding an SSRI for children who do not 
respond to initial treatment with CBT.  Taken together, the current evidence suggests that for 
non-responders to CBT, adding an SSRI while continuing CBT, rather than switching to  
SSRI monotherapy may be the best option to optimise outcomes regardless of the presence of 
a co-morbid Tic disorder.       
While the recommendation of some practice guidelines (AACAP, 2012) is that CBT 
combined with an SSRI is the preferred initial treatment in more severe cases, our review did 
not find any evidence for a difference in relative efficacy between CBT monotherapy and 
combined treatment that was related to the severity of the patient’s OCD. There was 
suggestive evidence (March et al., 2007) that degree of pre-treatment OCD-related 
psychosocial impairment may moderate the relative efficacy of CBT, SSRI and combined 
treatment. However, as this effect only trended towards significance, that study did not report 
on the direction or strength of any potential moderation effect on CBT for level of OCD 
impairment. Our finding regarding severity of OCD symptoms is consistent with the 
equivocal findings of studies directly examining the relative efficacy of CBT plus medication 
compared to CBT alone. While the influential POTS trial (POTS, 2004) reported that 
combined treatment was superior to CBT monotherapy this finding was not uniform across 
the two sites which conducted that trial.  A recent RCT (Storch et al., 2013) did not find a 
significant difference between combined CBT plus SRI treatment compared to CBT 
monotherapy while recent meta-analytic studies of treatments for pediatric OCD  (Ivarrson et 
al., 2015; Öst et al., 2016) concluded that there was no evidence to infer that combination 
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treatment was superior to CBT monotherapy. As pre-treatment symptom severity is a non-
specific predictor of a poorer response to SSRI monotherapy (Geller et al., 2003) as well as to 
CBT, the findings taken together indicate that currently there is no evidence about their 
relative efficacy to support any preference for combination treatment or CBT monotherapy as 
an initial treatment when symptoms are more severe.  
We did not find any evidence that the presence of another mental disorder or high 
levels of symptoms of anxiety, depression or disruptive behavior problems moderated 
response to CBT compared to another treatment. These factors were predictors of a poorer 
CBT response. However, they are also associated adversely with response to SSRI treatments 
(Geller et al., 2003).  We know that levels of depression are correlated with OCD symptom 
severity and this interrelationship may explain their association with treatment outcome. 
Studies (Storch et al., 2007; Torp et al., 2015) which examined OCD-specific and general 
psychological distress concurrently found that level of general psychological distress did not 
predict outcome of CBT after controlling for pre-treatment OCD-specific severity. These 
findings strongly suggest that other strategies to enhance CBT’s efficacy for severe OCD 
need to be developed and evaluated.  Tentatively, the evidence from the predictor studies 
summarised here confirm that strategies to enhance the child’s capacity to self-regulate 
emotional distress and to improve the parent’s abilities to manage the child’s general anxiety 
and disruptive behaviours may be worthwhile adjunct treatments to develop and evaluate. 
Family accommodation is already recognised as a key factor in maintaining symptoms and 
increasingly it is being targeted for change in current versions of CBT (Peris & Piacentini, 
2013).  
4.2 Limitations 
The findings about moderation effects of CBT need to be considered in the context of 
significant limitations and risks to bias in the review arising from three sources. First, there 
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were only a small number of studies which examined specific moderators and these 
individual studies have small sample sizes. Because the numbers needed to detect interactions 
are significantly higher than for between treatment differences (Aquinis 2005; Pincus et al., 
2001) moderator analyses were underpowered. The non-significant results reported, 
therefore, are not able to be validly interpreted. Given this, it is important not to exclude 
factors such as degree of OCD-related impairment and parental psychopathology from 
continued exploration as potential moderators.  In addition, because of the small number of 
participants in each treatment, the unpacking of significant interactions resulted in numbers in 
the subgroups stratified by level of the moderator which were well below the numbers 
recommended for valid inferences from subgroup differences (Pincus et al., 2011). For 
example, there were only 12 children in the subgroup with a family history who received 
CBT (Garcia et al., 2010) and only 3 in the subgroup with tics who received CBT (March et 
al., 2007). Caution is also needed in interpreting findings from single studies (Barrett et al., 
2004; Garcia et al., 2010) where multiple comparisons are undertaken without consideration 
of inflated false positives.  
The second source of bias is the substantial clinical and methodological variability 
particularly in the predictor studies arising from difference in the nature of the CBT treatment 
such as its components, delivery, duration and intensity, recruitment and assessment of the 
participants. While we included statistical variability in the decision to pool individual 
estimates and used random-effect models to reduce effects of methodological heterogeneity, 
clinical heterogeneity limits the ability to generalise from the pooled estimates to 
expectations about the delivery of CBT in clinical practice.  
The third area of bias is that many studies examined multiple outcomes without 
adjusting the experiment-wise error rates reducing the confidence in the result for CY-BOCS.  
We used CY-BOCS total as the primary outcome to reduce the risk of reporting on false 
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positives and to better allow comparability between studies. Other limitations of the 
individual predictor studies include non-reporting of values of estimates for non-significant 
results; lack of clarity in number of participants in specific analyses; lack of clarity in 
multiple reports of open trials with accumulating numbers, and failing to report first-order 
associations when using partial or multiple regressions.  
4.3 Directions for future research 
The significant limitations of the existing studies highlight the challenges that future 
work will need to address in order to avoid flawed conclusions from individual RCTs or 
systematic reviews and to limit the adoption of inaccurate clinical practices. While small 
subgroup sample sizes are ubiquitous in post-hoc moderator analyses from RCTs (Pincus et 
al, 2011) it is very important to confirm the moderation effects of an OCD family history and 
presence of Tic disorder. The limitations due to low power could be reduced in future meta-
analysis by merging and analysing individual patient level data across existing studies 
(Bloch, 2014). A stronger confirmation would be future RCTs in which participants are 
stratified according to levels of the moderator of interest (e.g., family history; presence of 
tics) and randomised to receive CBT, medication or combined treatment (Kraemer et al., 
2006).  .  Future prospective evaluations of possible moderators also need to focus more on 
factors where there are specified theoretical mechanisms to account for the differential 
treatment effects.  Given that CBT, unlike medication, deliberatively seeks via exposure and 
response prevention to enhance new learning by inhibiting existing emotional associations, 
these considerations could, for example, include the psychological and neurobiological 
mechanisms which underpin theses learning processes. Possible candidates for examination 
might be variability in children’s temperamental features such as behavioural inhibition as 
well as in neurophysiological variables such as brain-derived neurotropic factors which have 
been shown to facilitate inhibitory learning and also to predict poorer response to exposure 
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treatment in PTSD when identified by different genetic polymorphisms (Felmingham et al., 
2013).  The recent finding that aspects of brain glutamate, a neurophysiological factor 
involved in fear extinction, is a predictor of s CBT outcome for pediatric OCD  (O’Neil et al., 
2017) has the potential to move the area in important and productive new directions. Finally, 
pediatric OCD researchers are in a unique position of having almost universal agreement 
regarding the use of the CY-BOCS severity score as the gold-standard outcome measure.  
When researchers use this tool as a primary outcome, and report it as such, outcome 
comparisons are facilitated across different research groups.  
4.4. Conclusions   
In summary, this review provides the first systematic integration of the best evidence 
about the factors which differentiate treatment outcomes between CBT and other treatments 
for pediatric OCD. This evidence is very preliminary and more consistent findings across 
studies or further meta-analytic results combining sufficient individual patient data are 
required before firmer conclusions can be drawn. Tentatively, the review’s results suggest 
that having a first-degree family member with OCD and the presence of tics may be 
important considerations for initial choice of treatment and that the presence of tics may also 
be important when considering options for children who not respond to an initial course of 
CBT.  For researchers, findings of the review identify factors which could be further explored 
in order to better understand the mechanism by which CBT has its benefits and to improve 
treatment outcomes for a larger number of children and youth with OCD. The review also 
highlights the need for major methodological improvements in the design, implementation 
and reporting of future studies.  International cooperation via the establishment of a Pediatric 
OCD Consortium would be one way to enhance sharing and pooling of trial outcomes and 
facilitate appropriately sized studies so as to better answer questions regarding treatment 
moderators.  
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Figure 1:  Selection of studies. Note: OCD = Obsessive-compulsive Disorder; CBT – Cognitive-
behavioral therapy 
3,828 citations identified by the 
search strategy 
3759 citations were excluded due to 
being duplicates (n = 612) or due to 
non-relevance or the information 
provided in the abstract not meeting 
the inclusion criteria (n = 3147).  
 
69 full-text publications were 
obtained for assessment against the 
inclusion criteria  
35 retained for review:   
 
4 - publications meet the inclusion criteria for 
moderator analysis. 
1 -  publication meet the criteria for both 
moderator and predictor analyses. 
30 - publications meet inclusion criteria for 
34 publications excluded: 
26 – No analyses of moderators or predictors; 
3 – Predictors not measured at baseline; 
2 – Predicted outcome not OCD  
3-  No CBT alone arm or no disaggregated 
results 
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Table 1: Characteristics of studies included in CBT effect moderator review 
 
 Study: first 
author, year 
(total no. of 
subjects) 
Participant 
type 
 Diagnosis  Outcome 
measures 
Moderator  
(Baseline 
measure - 
continuous 
unless stated 
otherwise) 
Comparisons  Mean 
age, 
years 
(SD) 
Range 
Female 
(%) 
 
1 Barrett et al., 
2004  
(n = 77) 
Recruited 
from 
community 
(Australia)  
 ADIS-P CY-BOCS Child age 
Taking 
medication 
(yes/no) 
CBT(Ind.) v 
CBT (Group) 
v WL 
10.75 
(2.54) 
7 to 
17 
years 
50.7  
 
 
 
 
 
2 March et al., 
2007 
(n = 112) 
Recruited 
from 
community 
(USA) 
POTS  
 ADIS-C 
CY-BOCS>16 
CY-
BOCS 
Presence of 
tics (yes/no) 
CBT v 
Sertraline v 
Combined 
(CBT+ 
Sertaline) v 
PBO 
11.7 
(2.7) 
10 to 
18 
years 
50  
 
 
 
 
3 Garcia et al., 
2010 
(n = 112) 
Recruited 
from 
community 
(USA) 
POTS  
 ADIS-C 
CY-BOCS>16 
CY-
BCOS 
Age  
Gender 
(Male/Female) 
Household 
income 
Severity  
Impairment 
Insight 
Co-morbid  
Internalizing 
(yes/no) 
Co-morbid  
Externalizing 
(yes/no) 
Anxiety 
symptoms 
Externalizing 
symptoms 
Parental 
psychopathology 
(yes/no) 
OCD Family 
History (1st 
degree 
relative)(yes/no) 
Family 
functioning 
Family 
accommodation 
 
CBT v 
Sertraline 
v 
Combined 
(CBT + 
Sertraline) 
v PBO 
11.7 
(2.7) 
10 to 
18 
years 
50  
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Note. ADIS-Anxiety Disorder Interview Schedule C – Child version; P- Parent version. K-SADS – 
Schedule of Affective Disorders and Schizophrenia for School-aged Children - Present and Lifetime 
version; CY-BOCS Child Yale-Brown Obsessive-Compulsive Scale; PBO- pill placebo; POTS – Pediatric 
Obsessive-compulsive Treatment Study; NordLOTS- Nordic Long-term OCD Treatment Study; WL- 
Waitlist  
 
 
Table 2: Risk of bias assessment of studies (Criteria from Pincus at al., 2011)  
 
4 Bolton et al., 
2011 
 (n = 96) 
Recruited 
from 
community 
(UK) 
 
 ADIS-C/P CY-BCOS Child age 
(Continuous 
and Binary: 
Younger < 13 
years; Older 
>= 13 years)  
Standard CBT 
v Brief CBT v 
WL 
14.4 
(2.4) 
10 to 
18 
years 
 
 
59.4  
5 Skarphenedinson 
et al., 2015 
(n = 50) 
Recruited 
from 
community 
 (Norway) 
Non-
responders 
to initial 
CBT(post-
treatment 
CY-BOCS 
>= 15) 
from 
NordLOTS 
 
 K-SADS-PL 
CY-BOCS>16 
CY-
BCOS 
Presence of 
tics (yes/no) 
Continued 
CBT v 
Sertraline 
12.8 
(2.7) 
7 to 
17 
years 
51.3  
 Study (total 
no. of 
subjects) 
Moderator(
s) 
a-
priori/pos
t-hoc  
Plausible/ 
explorato
ry    
 Measured  
prior to 
randomiz
ation 
Power 
analysis 
(yes/no) 
Adequate 
N 
(smallest 
n)  
Valid 
baseline 
measures  
Test  
Pooled 
effect size 
and 95% 
CIs (no/yes) 
Differe
nce for 
each 
group 
(Yes/No
) 
Replicat
ed 
(Yes/no
)  
 
 Barrett et 
al., 2004  
(n = 77) 
Age; 
Post-hoc 
Exploratory 
   Yes Not 
reported  
N=6 
(smallest 
Yes Yes – no 
statistics 
reported  
Not 
require
d 
 
 Yes 
(Bolton, 
Garcia 
for age) 
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Table 3.  Results of moderator analysis review with total CY-BOCS as outcome; moderator; 
Study; test of interaction; significance of test; for subgroup comparisons n, effect sizes (95% 
CI). 
Moderator  Study Test of 
interaction 
p value Sub-group analysis for 
significant interaction 
Age 
(continuous) 
Barrett et al., 
2004  
Not reported           ns  
 Bolton et al., 
2011  
F (2, 89) = 
0.08         
p = 0.45  
 Garcia et al., 
2010 
F (3,104) = 
0.11      
p > .1  
Age (young v 
old)# 
Barrett et al., 
2004 
Not reported ns  
 Bolton et al., 
2011 
F (1,70) 
=0.52         
 p = 0.48  
OCD 
medication 
(Yes/No) 
Barrett et al., 
2004 
Not reported           ns  
medication 
status 
group)  
 
 March et 
al., 2007 
(n = 112) 
Presence of 
tics 
Post-hoc 
Plausible 
(evidence-
based)  
 Yes Not 
reported 
N= 3 
(smallest 
group) 
 Yes Yes 
No effect 
size 
Yes No  
 
 
 
 
 Garcia et 
al., 2010 
(n = 112) 
Family 
history; 
age; 
various 
Post-hoc 
Exploratory 
 Yes Not-
reported  
N = 11  
(smallest 
group) 
 Yes 
 
Yes 
 No effect 
size 
Yes – 
for 
signific
ant 
interact
ion 
Yes 
(Barrett
, Bolton 
for 
age); 
No 
otherwi
se 
 
 
 
 
 
  
Bolton et 
al., 2011 
 (n = 96) 
Age 
 
Post-hoc 
Exploratory 
 
  
Yes 
 
Not 
reported 
N= 15 
(smallest 
group) 
 
Yes  
 
Yes 
No effect 
size 
 
Not 
require
d 
 
 
Yes 
(Barrett
, Garcia 
for age) 
 
  
Skarphened
inson et al., 
2015 
(n = 50) 
Presence of 
tics 
 
A-priori 
Plausible 
(evidence-
based) 
  
Yes 
 
Not 
reported 
N= 5 
(smallest 
group) 
  
Yes 
 
Yes  
No effect 
size 
 
 
Yes 
 
No 
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Presence of 
tics (Yes/No) 
March et al., 
2007 
χ2 = 12.32      p < 
.006 
Yes CBT (n = 3) v PBO 
(n=5) (ES=1.63; 0.005 to 
3.27)* 
    No CBT (n=25) v PBO (n 
=23) (ES=2.59; 1.82 to 
3.36)* 
    Yes Comb.(n=4) v PBO 
(n=5) (ES=3.94; 1.69 to 
6.18)* 
    No Comb.(n=24) v PBO (n 
=23) (ES=3.95; 2.97 to 
4.94)* 
    Yes Sert.(n=5) v PBO (n=5) 
(ES=-0.20; – 1.44 to 1.04) 
        No Sert.(n =23) v PBO (n 
=23) (ES=1.99; 1.29 to 
2.70)* 
 Skarphedinson 
et al.,  
β= 
0.06(0.023)    
 p < .05 Yes Sert. (n=7) v cont. CBT 
(n=7) (ES= -2.62;-4.25 to -
1.11)* 
 2015   No Sert (n=17) v cont. CBT 
(n=21) (ES= 0.16; -0.47 to 
0.79) 
Family 
History 
(Yes/No) 
Garcia et al., 
2010 
 F (3,104) = 
2.70     
 p < .05 Yes CBT (n = 12) v PBO 
(n=11) (ES=0.25; -0.58 to 
1.07) 
     No CBT (n=17) v PBO (n 
=16) (ES=1.63; 0.83 to 
2.41)* 
     Yes Comb (n=11) v PBO 
(n=11) (ES=1.11; 0.21 to 
2.01)* 
     No Comb.(n=16) v PBO (n 
=16) (ES=2.82; 1.85 to 
3.77)* 
     Yes Sert. (n=11) v PBO 
(n=11) (ES=0.74;-0.12 to 
1.61)   
     No Sert. (n= 16) v PBO 
(n=16) (ES= 0.81; 0.09 to 
1.50)* 
Gender Garcia et al., 
2010 
F (3,104) = 
0.73     
ns  
Household 
income 
`` F (6,90) = 
0.57       
ns  
OCD severity `` F (3,104) = 
1.01     
ns  
COIS-P `` F (3,96) = 
1.94            
ns^  
COIS-C `` F (3,89) = ns  
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2.06       
Insight `` F (8,79) = 
0.69               
ns   
ADIS-C 
internal 
`` F (3,100) = 
0.52     
ns  
ADIS-C 
external 
`` F (3,100) = 
0.70     
ns  
Anxiety 
symptoms 
`` F (3,91) = 
0.88       
ns  
External 
symptoms 
``  F (3,88) = 
0.99       
ns  
BSI ``  F (3,92) = 
2.04       
ns   
FAM-III ``  F (3,96) = 
0.12       
ns  
FAS-PR ``  F (3,88) = 
1.32       
ns  
  
Note: ns – not significant p > .05; # cutoff for young group < 13 years; * p < .05; ^ reported 
as p < .05 in Garcia et al., 2010; Sert = sertraline group; PBO = pill placebo control; Comb = 
Combined CBT plus sertraline group; COIS-P = Child Obsessive-Compulsive Impact Scale–
Parent Report; COIS-C = Child Obsessive- Compulsive Impact Scale–Child Report; ADIS-C 
=Anxiety Disorder Interview Schedule-Child version; BSI = Brief Symptom Inventory; 
FAM-111= Family Assessment Measure-III; FAS-PR = Family Accommodation Scale– 
Parent Report. 
 
 
Table 4. Outcomes for predictors: Domain of predictor, predictor; study; statistical test; effect 
size r (95% CI), significance, number of participants, and for Pooled estimates: test, pooled 
effect size r (95%CIs), significance, total N and number of studies (k) 
 
Predictor (Domain)    Study   Test    Effect size r (95% 
CIs)   p value  n 
Demographic 
Age   Piacentini, et al., 2002 not reported   
   ns   42 
   Farrell, et al., 2010  F = 2.50  r = .14 (-.17 to 
.42)   p > .05   33 
   Rudy, et al., 2014  r = .10  r = .10 (-.13 to 
.32)   p > .05   78 
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   Torp, et al., 2015  t = 2.84 r = .17 (.05 to .29)
   p < .05   269 
   Pooled (random effects) z = 2.08 r = .15 (.05 to .25)
   p = .003  380 (k=3)    I
2 
 = 0% 
Sex   Piacentini, et al., 2002 not reported   
   ns   42 
   Farrell, et al., 2010  F = .063  r = .04 (-.27 to 
.36)    p > .05   35 
   Rudy, et al., 2014  r = .33    r = .33 (.12 to .52)
   p < .05   78 
   Torp, et al., 2015  t = 0.55    r = .03 (-.09 to 
.15)   p = .58   269 
Not pooled 
I
2 
 = 65.7% 
SES   Torp, et al., 2015  t = 0.19    r = .01 (-.11 to 
.13)   p = .85   269 
 OCD-related variables   
 OCD severity  Lewin, et al., 2011  β = .33  r = .33 (.03 to .58)
   p = .04   41 
Piacentini, et al., 2002 r = .34  r = .34 (.04 to .58)  
   p = .029  42 
    Rudy, et al., 2014  r = .29  r = .29 (.07 to .48)
   p < .05   78 
    Torp, et al.,  2015  t = 3.07 r = .19 (.07 to .30)
   p < .002   269 
    Wolters, et al., 2016  F = 0.29 not able to 
estimated   p = .75   58 
    Pooled (random effects) z = 4.91 r = .24 (.14 to .32)
   p < .001  430 (k=4) 
    I
2 
 = 0% 
 Impairment  Piacentini, et al., 2002 r =-.44   r = .44 (.15 to 
0.66)   p = .007   42 
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Ruby, et al., 2014  r = .17  r = .17 (-.06 to 
.38)   p < .05   78 
    Torp, et al., 2015  t = 3.71 r = .15 (.03 to .26)
   p = .16   269 
(Social) Piacentini, et al., 2002 r = .49  r = .49 (.22 to 
0.69)   p = .008  42 
(Academic) Piacentini, et al., 2002 r = .42  r = .42 (.13 to 
0.64)   p = .025  42 
   Pooled (random effects) z = 2.70 r = .21 (.06 to .36)
   p = .007  389 (k=3) 
    I
2 
 = 43.38% 
Age of onset  Nakatani, et al., 2011  F = 1.64 r = .12 (-.07 to 
.31)      p = .21   109 
 Duration of illness Torp, et al., 2015  t = 1.36 r = .08  (-.04 to 
.20)   p = .18   269  
 Type     
             (Somatic) Storch, et al., 2008  F = 1.06 r = .13 (-.12 to 
.36)   p > .05   62 
               (Sexual) Fernandez, et al., 2013 F = 0.123 r = .03 (-.14 to 
.20)   p = .73   153  
        (Aggressive) Storch, et al., 2008  χ2 = 3.4  r = .19 (-.02 to 
.38)   p = .06   92  
 (Transformation) Monzani et al., 2015  F = 0.858 not able to 
estimated                           p = .36   189 
Concurrent Treatment 
Medication  Piacentini, et al., 2002 χ2 = 0.35 r = .09 (-.21 to 
0.38)   p = .6   42 
    Himle, et al., 2003  t = 0.291  r = .07 (-.41 to 
0.52)   p = .77   18 
    Storch, et al., 2007  F = 0.8 r = .14 (-.17 to 
.42)    p = .38   39  
    Farrell, et al., 2010   F= 0.68 r = .18 (-.25 to 
.53)   p > .05   33 
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    Fernandez, et al., 2012 F = 1.27 r = .09 (-.07 to 
.26)   p = .27   153 
    Pooled (random effects) z = 1.74 r = .11 (-.01 to 
.22)   p = .081  285 (k=5) 
I
2 
 = 0% 
Co-morbidity 
 Depression (disorder) Brown, et al., 2014  β = 0.19 r = .19 (-.07 to 
.42)   p < .05   61 
    Farrell, et al., 2012  not reported   
    ns   28 
 Depression severity Piacentini, et al., 2002 not reported   
   ns   nr 
    Brown, et al., 2014  β = .26  r = .26 (.07 to .44)
   p < .05   98 
    Leonard, et al., 2014  F = 1.07 r = .16 (not able to 
estimated)  ns   126 
    Torp, et al., 2015  t = 2.82 r = .17 (.05 to .28)
   p < .005  269 
    Lewin, et al., 2011  not able to estimated 
   Pooled (random effects) z = 4.13 r = .19 (.10 to .27)
   p < .001  493 (k=4) 
    I
2 
 = 0% 
Tics/Tourette’s Piacentini, et al., 2002 not reported   
   ns   42 
Himle, et al., 2003  F = 1.32 r = .26 (-.19 to 
.59)   p > .05   19 
    Bennett, et al., 2015  F = 1.24 r = .14 (-.11 to 
.38)   p = .22   58 
    Torp, et al., 2015  t = 1.81  r = .11 (-.01 to 
.23)   p =.07   269 
    Hojgaard, et al., 2017  t = 1.02 r = .06 (-.06 to 
.19)   p = .309  269 
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    Pooled (random effects) z = 2.263 r = .09 (-.07 to 
.24)   p = .267  615 (k=4) 
    I
2 
 = 0% 
ASD   Farrell, et al., 2012   not reported  
    ns   38 
    Wolters, et al., 2016  F = 2.09 not able to 
estimated   p =.15   58 
Anxiety   Piacentini, et al., 2002 r = .38  r = .38 (.09 to .61)
   p =.043  42 
    Torp, et al., 2015  t = 2.33 r = .14 (.02 to .26)
   p = .02   269  
ADHD   Farrell, et al., 2012  χ2 = 3.99  r = .35 (.01 to .63)
   p = .06   31 
Temper outbursts  Krebs, et al., 2012  B = 1.15 r = .50 (-.51 to 
.87)   p = .329  109 
Any disorder  Storch, et al., 2008  r = .39  r = .39 (.20 to .55)
   p < .001  96 
    Farrell, et al., 2012  not reported (post-treatment) 
   ns   43  
    Farrell, et al., 2012 (f/up) r = .37  r = .37 (.07 to .60)
   p < .005  43 
    Rudy, et al., 2014  r =.12  r = .12 (- .11 to 
.33)   p > .05   78 
   Pooled (random effects) z = 3.04 r = .29 (.11 to .46)
   p = .002  217 (k=3) 
    I
2 
 = 48.57% 
Internalizing severity Rudy, et al., 2014  r = .30  r = .30 (.08 to .49)
   p < .05   78 
    Torp. et al., 2015  t = 3.33 r = .20 (.08 to .31) 
   p < .001  269  
Int disorder  Torp, et al., 2015  t = 1.48 r = .09 (- .03 to 
.21)   p =.139  269 
Moderators of CBT for pediatric OCD 39 
 
Externalizing severity Rudy, et al., 2014  r = .11  r = .11 (-.12 to 
.33)    p < .05   78 
   Torp, et al., 2015  t = 2.37 r = .14 (.02 to .26) 
   p = .017  269 
Ext. disorder  Torp, et al., 2015  t = 0.10 r = .01 (- .11 to 
.13)   p = .917  269 
Sleep problems Ivarsson,et al.,  2016  g = .32  r = .15 (.03 to .27)
   p < .001   269 
Family functioning 
 Family Climate Perris, et al., 2012a (binary) χ2 = 17.45 r = .60 (.35 to.77)
   p = .001  49 
    Perris, et al., 2012a (number)  χ2 = 19.74 r = .63 (.40 to .79)
   p < .0001   49 
 Expressed Emotion Perris, et al., 2012b  not reported   
   ns   41 
 Family accommod. Rudy, et al., 2014  r = .25  r = .25 (.03 to .45)
   p < .05   78 
    Torp, et al., 2015  t = 1.99 r = .12 (.01 to .24)
   p = .047  269 
    Merlo, et al., 2011  r = .32  r = .32 (.03 to .56)
   p < .05   45
 
   Pooled (random effects) z = 3.07 r = .19 (.07 to .29)
   p = .002  392 (k=3) 
    I
2 
 = 12.82% 
Parental psy. disorder Torp, et al., 2015  t = 1.00 r = .06 (- .06 to 
.18)   p = .32   269  
 Family OCD history Torp, et al., 2015  t = 1.09 r = .07 (- .05 
to.19)   p = .28   269  
Neuropsychology functioning 
 Memory (recall) Flessner, et al., 2010  F = 6.68   r = .60 (.10 to .82)
   p = .29   12 
 Emotional control McNamara, et al., 2014 β = .207 r = .21 (-.06 to 
.45)   p < .05   56 
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Pathophysiology 
 Glutamate (vPCC) O’Neil et al., (2017)     r = .81  r = .81  (.57 to .92) 
   p < 0.001  20 
 
Highlights 
 Individual treatment response to CBT for pediatric OCD is considerably variable 
 The first systemic review of moderators of CBT outcomes against other treatments  
 Evidence is post-hoc, from single RCTs, has small Ns and requires replication 
 Co-morbid tics and a family OCD history may moderate CBT outcomes against 
sertraline 
 Studies with larger Ns and testing a-priori and plausible hypotheses are required   
 
